Telix Pharmaceuticals agreed to acquire German radiopharmaceutical manufacturer ITM Isotope Technologies Munich SE in a deal valued at $1.65 billion upfront, with potential additional milestone payments that could bring the total to $2.35 billion. The transaction combines ITM’s isotope manufacturing footprint with Telix’s radiopharma pipeline, aiming to scale production and broaden development capability in targeted radionuclide therapies. The acquisition matters for the competitive landscape because it targets an operating bottleneck in the radiopharmaceutical supply chain—radioisotope manufacturing—at the same time Telix is expanding clinical and commercial ambitions. Analyst commentary around the deal emphasizes the strategic fit with radiopharma R&D and manufacturing networks. The merger has also been shaped by ITM’s recent setback in relation to a drug milestone, which Telix noted as part of the deal’s conditions. The result is a high-stakes consolidation bet that Telix can move faster once regulatory and commercial gates clear.